Table 3 Treatment-related adverse events.

From: Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

 

Four-drug group (n = 22), n (%)

Three-drug group (n = 108), n (%)

Grade 1

Grade 2

Grade 3

Grade 1

Grade 2

Grade 3

Fatigue

14 (63.6)

3 (13.6)

0 (0)

75 (69.4)

17 (15.7)

1 (0.9)

Constipation

13 (59.1)

4 (18.2)

0 (0)

58 (53.7)

11 (10.2)

1 (0.9)

Anorexia

9 (40.9)

2 (9.1)

0 (0)

70 (64.8)

11 (10.2)

3 (2.8)

Insomnia

4 (18.2)

1 (4.5)

1 (4.5)

28 (25.9)

12 (11.1)

1 (0.9)

Somnolence

5 (22.7)

0 (0)

0 (0)

2 (1.9)

0 (0)

0 (0)

Dizziness

5 (22.7)

0 (0)

0 (0)

17 (15.7)

0 (0)

1 (0.9)

Headache

5 (22.7)

0 (0)

0 (0)

31 (28.7)

0 (0)

0 (0)

ALT increased

3 (13.6)

0 (0)

1 (4.5)

18 (16.7)

5 (4.6)

0 (0)

AST increased

3 (13.6)

1 (4.5)

0 (0)

17 (15.7)

3 (2.8)

0 (0)

Diarrhea

2 (9.1)

2 (9.1)

0 (0)

8 (7.4)

2 (1.9)

2 (1.9)

Abdominal pain

1 (4.5)

0 (0)

0 (0)

7 (6.5)

0 (0)

0 (0)

Palpitations

1 (4.5)

0 (0)

0 (0)

4 (3.7)

0 (0)

0 (0)

Hyperglycemia

1 (4.5)

0 (0)

0 (0)

9 (8.3)

1 (0.9)

0 (0)

  1. ASL, aspartate aminotransferase; ALT, alanine aminotransferase. No grade 4 and 5 treatment-related adverse events were reported.
Back to article page